Related Experiment Video

Updated: Sep 25, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

The 2021 Global Lung Cancer Therapy Landscape

Dhruba Deb1, Amy C Moore2, Upal Basu Roy2

  • 1Department of Biomedical Engineering, Columbia University, New York, New York.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 30, 2022
PubMed
Abstract

Insights

Lung cancer drug development shows a strong pipeline with many therapies in advanced clinical trials. The field is increasingly biomarker-driven, with expanding immuno-oncology targets beyond PD-L1.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Research

Background:

  • The lung cancer treatment landscape has significantly changed in the last decade.
  • A comprehensive analysis of the global drug development pipeline for lung cancer is lacking.

Purpose of the Study:

  • To systematically analyze the current global landscape of therapeutic entities (TEs) in lung cancer drug development.
  • To identify trends in preclinical and clinical development for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Main Methods:

  • Curated and analyzed a comprehensive list of 707 TEs.
  • Included TEs in preclinical development and active clinical trials for lung cancer.

Main Results:

  • Observed a consistent forward trajectory in the lung cancer drug development pipeline.
  • Most TEs are in advanced clinical trial stages (Phase II/III).
  • Targeted therapies remain dominant outside of immuno-oncology; immuno-oncology targets are diversifying beyond PD-L1 inhibitors.

Conclusions:

  • The lung cancer drug development portfolio is robust, with numerous preclinical and clinical TEs.
  • Future lung cancer treatment strategies will likely be increasingly driven by specific biomarkers.
  • Expanding immuno-oncology targets suggest novel therapeutic avenues are emerging.
Keywords:
Clinical trialsNon–small cell lung cancerPreclinical researchSmall cell lung cancer

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.9K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
531
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
687
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K